KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Invested Capital (2016 - 2025)

Historic Invested Capital for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Invested Capital fell 122.06% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 122.06%. This contributed to the annual value of $1.9 billion for FY2024, which is 261.72% up from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Invested Capital is $1.9 billion, which was down 122.06% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Invested Capital peaked at $2.6 billion during Q2 2021, and registered a low of $1.7 billion during Q2 2025.
  • Moreover, its 5-year median value for Invested Capital was $1.9 billion (2024), whereas its average is $2.0 billion.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Invested Capital soared by 18592.08% in 2021 and then plummeted by 2224.38% in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Invested Capital (Quarter) stood at $2.4 billion in 2021, then decreased by 21.84% to $1.9 billion in 2022, then increased by 0.39% to $1.9 billion in 2023, then grew by 2.62% to $1.9 billion in 2024, then dropped by 0.83% to $1.9 billion in 2025.
  • Its Invested Capital was $1.9 billion in Q3 2025, compared to $1.7 billion in Q2 2025 and $1.8 billion in Q1 2025.